Loss of <i>Parp7</i> increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and despite low incidence rates, it remains the sixth leading cause of cancer related deaths worldwide. Immunotherapy, which aims to enhance the immune system's ability to recognize and eliminate cancer cells, has emerged as a promising approach in the battle against PDAC. PARP7, a mono-ADP-ribosyltransferase, is a negative regulator of the type I interferon (IFN-I) pathway and has been reported to reduce anti-tumour immunity.

Methods

We used murine pancreatic cancer cells, CR705, CRISPR/Cas9, in vivo tumour models and spectral flow cytometry to determine the role of PARP7 in pancreatic tumour growth.

Results

Loss of Parp7 elevated the levels of interferon stimulated gene fac

SUBMITTER: Kannen V 

PROVIDER: S-EPMC11759301 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature